Evy Lundgren-Åkerlund

This inventor holds 10 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignees: Xintela Ab, Cartela Ab, Cartela R&d Ab. Active years: 2006-2021.

USPTO Granted Patents = 10 (Patent Applications = 3)

% Patents Active = 60.0

EPO Patents = 2

Average Co-Inventor Count = 1.1

ph-index = 4

Forward Citations = 42(Granted Patents)

Location History:

Bjarred, SE (2010 - 2018)
Bjärred, SE (2006 - 2021)

Company Filing History:

Years Active: 2006-2021

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10994022 - Detection and treatment of malignant tumours in the CNS (2021-05-04),

2. 10087253 - Monoclonal antibody capable of binding integrin alpha 10 beta 1 (2018-10-02),

3. 10081666 - Integrin heterodimer and a subunit thereof (2018-09-25),

4. 8895253 - Integrin heterodimer and a subunit thereof (2014-11-25),

5. 8105791 - Marker for stem cells and its use (2012-01-31),

6. 8048991 - Antibody to an integrin heterodimer and/or a subunit thereof (2011-11-01),

7. 8012696 - Monoclonal antibody capable of binding integrin alpha 10 beta 1 (2011-09-06),

8. 7749710 - Marker for stem cells and its use (2010-07-06),

9. 7452677 - Monoclonal antibody capable of binding integrin alpha 10 beta 1 (2008-11-18),

10. 7029858 - Integrin heterodimer and a subunit thereof (2006-04-18),

Title: Evy Lundgren-Åkerlund: Innovator in Cancer Treatment and Stem Cell Research

Introduction

Evy Lundgren-Åkerlund is a prominent inventor based in Bjärred, Sweden. She has made significant contributions to the fields of cancer treatment and stem cell research. With a total of 10 patents to her name, her work focuses on innovative methods for diagnosing and treating malignant tumors, as well as identifying and isolating mesenchymal stem cells.

Latest Patents

Among her latest patents is a groundbreaking invention concerning the detection and treatment of malignant tumors in the central nervous system (CNS). This invention involves methods for diagnosing and treating malignant neoplasms by detecting mammalian tissue that expresses the integrin alpha 10 subunit and administering a drug specific to this subunit. Another notable patent is a marker for mesenchymal stem cells (MSC), which comprises an integrin alpha 10 chain and/or an integrin alpha 11 chain. This marker is utilized in methods for identifying and isolating MSC, as well as in various applications related to the modulation and identification of these cells.

Career Highlights

Evy has worked with several companies throughout her career, including Xintela AB and Cartela R&D AB. Her innovative approaches and research have positioned her as a key figure in her field, contributing to advancements in medical science.

Collaborations

Evy has collaborated with notable professionals in her field, including Ramiro Gisler and Jan Talts. These collaborations have further enhanced her research and development efforts.

Conclusion

Evy Lundgren-Åkerlund's contributions to cancer treatment and stem cell research exemplify her dedication to innovation and scientific advancement. Her patents reflect her commitment to improving medical outcomes and understanding complex biological processes.